ST2 and CSF‐1 as potential druggable targets of inflammatory bowel diseases: results from two‐sample Mendelian randomization study

Jiarui Mi,Xia Wu,Xiaoyin Bai,Yang Yang,Hong Yang
DOI: https://doi.org/10.1111/cts.13442
2022-11-06
Clinical and Translational Science
Abstract:Novel druggable targets are warranted for Inflammatory bowel disease (IBD) treatment. We aimed to identify novel circulating proteins with causal associations with the risk of IBDs and provide potential therapeutic targets for IBD treatment. We performed a two‐sample Mendelian randomization study to explore the associations of 55 circulating biomarkers on the risk of IBD, Crohn's disease (CD), and ulcerative colitis (UC) by leveraging the summary statistics from large genome‐wide association studies and protein quantitative trait loci studies. The individual estimate was pooled together by meta‐analyses to estimate the causal effects of each outcome. In univariable MR, we identified several circulating proteins showed potential correlation with IBD, UC, and CD. Of note, we observed that a genetically proxied increased level of ST2 was associated with an elevated risk of IBD (odds ratios [ORs] 1.133, 95% CI 1.091‐1.176, P
medicine, research & experimental
What problem does this paper attempt to address?